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In this issue, Sorbara et al. (2014) demonstrate that axonal transport impairment is an early feature of neuro-
degeneration in multiple sclerosis models. This transport deficit is reversible by anti-inflammatory interven-
tion but, if untreated, can contribute to late-stage axonal dystrophy.Multiple sclerosis (MS) is the most com-
mon, chronic disabling neuroinflamma-
tory condition affecting young adults.
The clinical manifestations of MS are
variable but include motor dysfunction,
sensory and visual impairment, and neu-
ropsychological problems. Following the
first attack the disease course typically
comprises periods of relapse and remis-
sion. Approximately 50%–65% of pa-
tients then go on to develop secondary
progressive disease, with progressive
neurological decline without definite
remission between the acute relapses.
Ten to twenty percent of patients have
primary progressive MS and show no
remission after the first attack, instead
displaying progressive decline from the
outset. Regardless of the exact MS sub-
type, neurological decline is inevitable
and, within 25 years post diagnosis, about
half of patients require the permanent use
of a wheelchair (Compston and Coles,
2008). A recent study by Sorbara et al.
(2014) now explores how the neurode-
generation that is common to all MS pa-
tients and that directly drives disability is
promoted by deficits in axonal trans-
port—a key process for the maintenance
of axonal homeostasis and function.
The precise pathophysiological mecha-
nisms that cause MS remain to be fully
elucidated. However, the disease is
considered to be an autoimmune condi-
tion initiated by auto-reactive immune
cells that cross the blood-brain barrier
and target the central nervous system
(CNS). The inflammatory infiltrate leads
to the formation of lesions that are a key
disease feature and are characterized bythe presence of immune cells, demyeli-
nated axons, lower oligodendrocyte
numbers, transected axons, and glial
hypertrophy. The infiltration eventually
promotes continued activation of mac-
rophages that home to the CNS and
of resident microglia, thereby further
disseminating the inflammation and
ensuing demyelination and neuroaxonal
damage. Gradually, the neurodegenera-
tive process becomes self-perpetuating,
resulting in irreversible disability (Comp-
ston and Coles, 2008; Fugger et al.,
2009; Friese et al., 2014).
The immunological component is the
best understood etiopathological aspect
of MS, and its importance in the disease
has been emphasized by the findings of
large-scale genetic analyses (Beecham
et al., 2013), the identification of Epstein-
Barr virus as an environmental contributor
to MS (Sundqvist et al., 2012), and animal
model studies in which the MS-like dis-
ease experimental autoimmune encepha-
lomyelitis (EAE) can be induced through
immune activation (Fugger et al., 2009).
The appreciation of immune dysfunction
as a driver of MS development has had
a catalytic effect clinically: two decades
ago, the disease was only poorly treated
and there were no medications pre-
scribed to specifically treat MS, but today
there are some ten different immunomod-
ulatory drugs (IMDs) available (Figure 1).
However, despite this progress, these
IMDs have varying efficacy and are asso-
ciated with a number of unwanted side
effects ranging from flu-like symptoms
to malignancies and even fatal oppor-
tunistic infections (Bloomgren et al.,Neuron 84, De2012). Furthermore, even if they reduce
relapses, none of the IMDs ultimately pre-
vent or halt neurodegeneration.
The implications of this clinical
outcome are two-fold. First, it is now
apparent that there is an unmet need for
novel therapeutic strategies that can
specifically target neurodegeneration,
shifting the balance toward reduced neu-
roaxonal damage and increased neuro-
protection and/or regeneration. Second,
although CNS damage in MSmay be initi-
ated by the inflammatory infiltrate, neuro-
degeneration should not be considered
as the second phase of the disease but
as an early, concomitant process that
is already underway by the time of clin-
ical diagnosis (Friese et al., 2014). The
conceptual uncoupling of neuroaxonal
degeneration from the classical sequen-
tial view of MS disease course progres-
sion has spurred research to try to fill
in the gaps in our understanding of the
molecular and cellular mechanisms that
cause the degeneration. Axonal injury is
a critical event: axonal damage can
be detected even in MS lesion axons
that are still myelinated (Nikic et al.,
2011), and axonal loss perhaps provides
the best correlate of the neurological
disability seen in the disease. Although
the more traditional methodologies,
such as CNS tissue immunohistochem-
istry, have provided some information
regarding the pathogenic features of
axonal injury, the interrogation of the dy-
namics of axonal dysfunction has neces-
sitated technological advances such as
the use of in vivo two-photon imaging
(Misgeld and Kerschensteiner, 2006).cember 17, 2014 ª2014 Elsevier Inc. 1105
Figure 1. MS Drugs and the Spatial Distribution of Their Respective Targets
The majority of drugs available for MS or in clinical trials are immunomodulatory. While the exact mechanisms of action of many of these therapeutics have not
been fully elucidated, they can be broadly categorized into those that prevent the immune cell egress from secondary lymphoid organs (fingolimod), those that
regulate peripheral immune cell activation (e.g., IFNb, daclizumab), those that prevent immune cells from crossing the blood-brain barrier (natalizumab), and
those that are thought to further suppress inflammation in the CNS (e.g., laquinimod). By comparison, there is a striking lack of non-immunological drug targets
within the CNS, with perhaps the exception of axonal ion channels that become redistributed and dysfunctional upon axonal damage. Abbreviations are as fol-
lows: APC, antigen-presenting cell; ASIC1, acid-sensing ion channel 1; B, B lymphocyte; BDNF, brain-derived neurotrophic factor; DC, dendritic cell; DMF,
dimethyl fumarate; GLAT, glatiramer acetate; IFNb, type I interferon-beta; IL-10, interleukin-10; NK, natural killer lymphocyte; ODC, oligodendrocyte; PC, plasma
cell; T, T lymphocyte; Th1, T helper lymphocyte type 1; Th2, T helper lymphocyte type 2; Th17, T helper lymphocyte type 17; S1PR, sphingosine-1-phosphate
receptor; and VCAM1, vascular cell adhesion molecule 1.
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PreviewsThe paper by Sorbara et al. (2014) em-
ploys this technique to investigate the po-
tential role of impaired axonal transport in
MS neurodegeneration by directly assay-
ing organelle trafficking and microtubule
stability along individual spinal axons
following EAE induction.
Axonal transport is the process by
which cargo shuttles long distances be-
tween the neuronal cell body and synap-
ses along the axon; it is essential to
neuronal function and allows axons to be
supplied with lipids, proteins, and organ-
elles from the soma (through anterograde
transport), while components that require
degradation or recycling are trafficked1106 Neuron 84, December 17, 2014 ª2014back to the cell body (through retrograde
transport). Axonal transport impairment
has been described in the more classical
neurodegenerative diseases, but Sorbara
et al. (2014) now demonstrate that it is
also a prominent feature of neuroinflam-
matory lesions in MS-like disease. Using
mice in which the transport of single, fluo-
rescently-labeled organelles (mitochon-
dria in Thy1-MitoCFP mice and peroxi-
somes in Thy1-PeroxiYFP animals) can
be tracked along the spinal axons in vivo,
the authors compared transport in the
healthy as opposed to inflamed spinal
cord. Intriguingly, they found that trans-
port was not only reduced in the degener-Elsevier Inc.ating axons but also in the majority
of normal-appearing axons found in the
lesions, indicating that transport distur-
bances may promote and demarcate
the more pervasive axonal dysfunction
that precedes progressive degeneration.
Notably, the localized transport deficits
were detected acutely but also persisted
for a number of weeks in a chronic EAE
model. A net deficiency of organelle
delivery from the cell body to the synap-
ses was observed as anterograde rather
than retrograde transport was more
significantly affected. This also coincided
with organelle arrest in areas of neuro-
inflammation such that mitochondrial
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Previewsaccumulation, for example, was observed
within the lesions.
To better comprehend the mechanism
underpinning this impaired mitochon-
drial transport, the authors determined
whether or not damage to mitochondria,
which has been previously described
in lesions (Nikic et al., 2011), might
contribute to the observed deficit—espe-
cially as axonal transport itself is highly
energy demanding. However, there was
no correlation between altered mito-
chondrial morphology and impaired
transport rates. Microtubule stability
was also assessed, given the role of
this cytoskeletal component as a dy-
namic platform for trafficking along
axons, using quantitative immuno-
histochemistry for stabilization status
markers, and electron microscopy and
in vivo two-photon imaging with Thy1-
EB3-YFP mice to assay microtubule
orientation. The transport deficits were
observed prior to the marked microtu-
bule destabilization detectable in the
swollen axons found in lesions. This is
consistent with transport impairment
occurring in normal-appearing as well
as degenerating axons running through
lesions and perhaps also suggests that
microtubule destabilization marks more
permanent structural axon damage.
Finally, the establishment of axonal
transport deficiency as an early phenom-
enon in the development of progressive
axonal dystrophy led Sorbara et al.
(2014) to hypothesize that this deficit
could be reversed in axons that did not
show prominent structural damage:
such a reversal was noted as acute dis-ease subsided but also following the
administration of anti-inflammatory and
anti-oxidative interventions.
A challenge now is to determine how
closely the characteristics of axonal
transport deficits observed in models
of MS correspond to the human disease,
but studies such as that by Sorbara
et al. (2014) will help to more accurately
delineate the temporal relationship be-
tween the perceived cascade of
sequelae that are instigated by CNS
inflammation and that ultimately lead to
neurodegeneration. This is particularly
critical: to date, only a few potential
neuronal drug targets—chiefly ion chan-
nels— have been identified for MS
(Figure 1; summarized by Friese et al.,
2014), but with the advent of more trac-
table high-throughput screening ap-
proaches (Mei et al., 2014) and stem
cell technology-related advances in
our understanding of neuro-restorative
pathways (Yang et al., 2013), the even-
tual discovery of additional putative tar-
gets is anticipated. However, for the
benefits of such therapeutic manipula-
tion to be maximized, the window of op-
portunity must be defined so that the
progressive, long-term neurodegenera-
tive processes to be targeted can be
dissociated from shorter-term events
that may already be indirectly rectified
by the action of available IMDs. Consid-
ering the complexity and chronicity of
neurodegeneration in MS, a combinato-
rial treatment approach may very well be
required to keep inflammation at bay,
dampen down and contain neuroaxonal
damage and death, boost defensiveNeuron 84, Demechanisms, and promote remyelinaton
and repair.
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